PharmaResearch's Rejuran Cosmetic Enters 25 Costco Stores in U.S.
Predicted impact: Low
Cosmetic product entering 25 Costco stores; small relative to last year's revenue.
PharmaResearch파마리서치
214450 · KOSDAQ · ₩214450 · 파마리서치
₩231,500▲ ₩2,000 (0.87%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −56.65%
- Market cap
- ₩2.4T
- Enterprise value
- ₩2.2T
- P/E
- 13.0×
- P/B
- 3.2×
- Dividend yield
- 1.6%
- ROE
- 24.6%
- Net margin
- 30.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−58.7% from the high
₩228,500Today: ₩229,500 – ₩239,500₩561,000
Returns
- 1W−13.0%
- 1M−28.2%
- 3M−38.3%
- 6M−28.8%
- YTD−42.6%
- 1Y−56.6%
- Volume today
- 64,876
- 0.6× the 20-day average
- Traded today
- ₩15B
- Listed shares
- 10,389,648
- EPS (12 months)
- ₩17,873
- Earnings yield 7.7%
AI research · InitiationPharmaResearch: Strong Profit Growth and High Margins Alongside a 45.2% One-Year Share Price DeclineThe filed financials show rapid growth, margins near 40%, strong returns and almost no debt, and the valuation multiples have fallen from year-end 2025 levels and sit below the peers shown.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 34 of 100 (50 is a normal day for this stock).
- MomentumWeak-28.5% over the last month; the price is below its 20-day average.
- News impactLow5 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 26: sell ₩1.5B at the close (5.1% of 20-day average trading value)
On its 24 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 5.5% of trading value and pointed the same way 17 of 24 times.
- 2× KODEX KOSDAQ150 Leverage −₩1.3B
- -1× KODEX KOSDAQ150 Futures Inverse −₩108M
- 2× TIGER KOSDAQ150 Leverage −₩96M
- 2× RISE KOSDAQ150 Futures Leverage −₩28M
- -1× TIGER KOSDAQ150 Futures Inverse −₩3M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 11 funds.
- KODEX KOSDAQ1500.9%
- KODEX KOSDAQ150 Leverage2×0.9%
- TIGER KOSDAQ1500.9%
- RISE KOSDAQ1500.9%
- TIGER KOSDAQ150 Leverage2×0.9%
- ACE KOSDAQ 1500.9%
- KIWOOM KOSDAQ1500.9%
- SOL KOSDAQ1500.9%
Estimated from the funds' index or underlying stock.
Futures and options
All stock futures →Futures (2026-11): 229,500
Basis −0.86% · implied rate −19.8%
Open interest 5,061 contracts
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
PharmaResearch stock overview
PharmaResearch (파마리서치, KRX: 214450) is listed on KOSDAQ, in the Biotech & Pharma sector. Pharmaris Research's history begins in 2001 as a company importing and distributing overseas pharmaceuticals in Korea, and it has since developed its own PDRN/PN regenerative technology, producing regenerative medicines, medical devices and cosmetics at GMP-certified plants in Gangneung. Its shares closed at ₩231,500 on Oct 27, 2026, up 0.87% on the day, giving it a market value of ₩2.4T.
Key facts
- Market cap
- ₩2.4T
- Sector
- Biotech & Pharma
- Latest price change
- +0.87%
- As of
- Oct 27, 2026
- Main business
- Pharmaris Research's history begins in 2001 as a company importing and distributing overseas pharmaceuticals in Korea, and it has since developed its own PDRN/PN regenerative technology, producing regenerative medicines, medical devices and cosmetics at GMP-certified plants in Gangneung.
Quick answers about PharmaResearch
- What does PharmaResearch do?
- Pharmaris Research's history begins in 2001 as a company importing and distributing overseas pharmaceuticals in Korea, and it has since developed its own PDRN/PN regenerative technology, producing regenerative medicines, medical devices and cosmetics at GMP-certified plants in Gangneung. Its main products include the Rejuran skin-booster devices, Conjuran knee injection, Rejuran cosmetics and regenerative drugs, and its subsidiary Pharmaresearch Bio sells botulinum toxin Rientox. Products are sold to hospitals and clinics in Korea and exported to China, Japan, Europe and North America, as well as to consumers through retail and online channels.
- What is the market cap of PharmaResearch?
- The market capitalisation of PharmaResearch was ₩2.4T at the close on Oct 27, 2026.
- Who are the largest shareholders of PharmaResearch?
- According to the latest official filings, the largest reported holders are Jung Sang-soo (41.54%, as of Nov 12, 2025); PolishCompanyLimited (10.07%, as of Oct 16, 2024); National Pension Service (7.14%, as of Oct 2, 2026).
- When is the next earnings report from PharmaResearch?
- Korean companies rarely announce results dates in advance. Based on when PharmaResearch filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own PharmaResearch?
- Yes. The National Pension Service held 7.14% of PharmaResearch shares as of Oct 2, 2026.
Company profile
Pharmaris Research's history begins in 2001 as a company importing and distributing overseas pharmaceuticals in Korea, and it has since developed its own PDRN/PN regenerative technology, producing regenerative medicines, medical devices and cosmetics at GMP-certified plants in Gangneung. Its main products include the Rejuran skin-booster devices, Conjuran knee injection, Rejuran cosmetics and regenerative drugs, and its subsidiary Pharmaresearch Bio sells botulinum toxin Rientox. Products are sold to hospitals and clinics in Korea and exported to China, Japan, Europe and North America, as well as to consumers through retail and online channels.
Written by AI from the company's latest annual report.
- Korean name
- 파마리서치
- Sector
- Biotech & Pharma
- CEO
- 손지훈
- Founded
- Mar 2001
- Listed
- Jul 2015
- Listed shares
- 10,389,648
- Fiscal year ends
- Month 12
- Website
- pharmaresearch.com/
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
PharmaResearch Joins US Costco's 'Beauty Table', Expanding Offline Cosmetics Distribution
Predicted impact: Low
Costco beauty table listing is a small distribution expansion.
Medical Tourism Tailwind Fades; PharmaResearch Needs New Growth Engine [Click e-Stock]
Predicted impact: Low
Commentary on fading medical tourism demand; vague, no quantified impact.
Recent filings
See all- 5%+ holding reportOct 2, 2026
- Investor relations (IR) eventSep 1, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Preliminary earnings (consolidated)Aug 7, 2026
- Investor relations (IR) eventAug 6, 2026
Titles in Korean until English translations are added.
Also known as: PharmaResearch / 파마리서치 / 214450 / KRX:214450
Source: KRX statistical information